NTRB Nutriband Inc. - Common Stock
NASDAQ · Pharmaceuticals close Oct 2, 2026NTRB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
NTRB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
| Ex-date | Split | Type |
|---|---|---|
| Aug. 12, 2022 | 583-for-500 | Forward |
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
Not enough fundamentals data to compute this ratio group yet.
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| March 31, 2026 | $-0.08 | $-1.93 | 95.9% | |
| Dec. 31, 2025 | $-0.32 | $-2.17 | 85.3% | |
| Sept. 30, 2025 | $-0.18 | $-0.17 | -3.8% | |
| June 30, 2025 | $-0.12 | $-0.16 | 26.5% | |
| March 31, 2025 | $-0.51 | $-0.12 | -316.7% |
Institutional owners (13F) 19 filers · $2.0M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 2 (-1 vs prior Q) | 0 (-7 vs prior Q) | 2 (-1 vs prior Q) | 4 (+1 vs prior Q) | -22K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $920,431 | 202,738 | 44.97% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $558,017 | 174,927 | 27.26% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $199,396 | 62,494 | 9.74% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $80,104 | 25,111 | 3.91% | Shares |
| STATE STREET CORP | $79,642 | 24,966 | 3.89% | Shares |
| CITADEL ADVISORS LLC | $60,597 | 18,996 | 2.96% | Shares |
| NORTHERN TRUST CORP | $36,908 | 11,570 | 1.80% | Shares |
| Haven Private, LLC | $36,258 | 11,366 | 1.77% | Shares |
| BlackRock, Inc. | $34,012 | 10,662 | 1.66% | Shares |
| OSAIC HOLDINGS, INC. | $11,752 | 3,684 | 0.57% | Shares |
| Vanguard Global Advisers, LLC | $8,613 | 2,700 | 0.42% | Shares |
| WELLS FARGO & COMPANY/MN | $8,294 | 2,600 | 0.41% | Shares |
| Tower Research Capital LLC (TRC) | $6,721 | 2,107 | 0.33% | Shares |
| UBS Group AG | $2,144 | 672 | 0.10% | Shares |
| Christopher J. Hasenberg, Inc | $1,574 | 200 | 0.08% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $1,426 | 466 | 0.07% | Shares |
| CLEAR STREET LLC | $787 | 100 | 0.04% | Shares |
| BARCLAYS PLC | $61 | 19 | 0.00% | Shares |
| HARBOUR INVESTMENTS, INC. | $10 | 3 | 0.00% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Gareth Sheridan ×2 filings | Sept. 15, 2026 | 14.20% | Amendment | Passive investment | SEC |
| Serguei Melnik | March 13, 2025 | 9.39% | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Jan. 23, 2024 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 4 insiders · 3 officers · 3 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Gareth Sheridan | CEO | March 20, 2024 A | 1,510,000 | 0 | 0 | $0 |
| Gerald Goodman | Chief Financial Officer | June 6, 2024 M | · | 0 | 0 | $0 |
| Serguei Melnik | President and Secretary | March 20, 2024 A | 827,999 | 0 | 0 | $0 |
| Michael Davidov | Director | July 31, 2018 A | 5,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
NTRB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
1 analysts · 2026-10-01Mean target $15.00 +106.0%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| NTRB | · | · | · | · | · | · |
| PLYX | · | · | · | · | -193.7% | · |
| NMRA | $312M | -1.2 | · | · | -165.2% | · |
| CGTX | $120M | -4.2 | · | · | -113.7% | · |
| NTHI | · | -2.6 | -51.8% | · | · | · |
| TELO | $46M | -4.0 | · | · | -325.7% | · |
| VRCA | $143M | -4.9 | 370.2% | -50.3% | -492.8% | · |
| RFL | · | -1.6 | 44.0% | -3328.2% | -34.6% | · |
| CING | · | · | · | · | · | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.